2018
DOI: 10.1080/15384101.2018.1556064
|View full text |Cite|
|
Sign up to set email alerts
|

RETRACTED ARTICLE: TGF-β secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
50
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 60 publications
(50 citation statements)
references
References 22 publications
0
50
0
Order By: Relevance
“…Rosano et al 28 revealed that miR-29a-3p can identify patients with colorectal cancer who are responding to anti-angiogenic therapy. Zhang et al 29 reported that miR-34a played an anti-tumor role by inhibiting the expression of VEGF in colorectal cancer. Double luciferase reporter assay revealed that miR-519d-3p could inhibit the fluorescence intensity of VEGF 3ʹ-UTR-wt vector significantly, but not VEGF 3ʹ-UTR-mut vector.…”
Section: Discussionmentioning
confidence: 99%
“…Rosano et al 28 revealed that miR-29a-3p can identify patients with colorectal cancer who are responding to anti-angiogenic therapy. Zhang et al 29 reported that miR-34a played an anti-tumor role by inhibiting the expression of VEGF in colorectal cancer. Double luciferase reporter assay revealed that miR-519d-3p could inhibit the fluorescence intensity of VEGF 3ʹ-UTR-wt vector significantly, but not VEGF 3ʹ-UTR-mut vector.…”
Section: Discussionmentioning
confidence: 99%
“…TAMs are able to produce angiogenic factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor and transforming growth factor β. TAMS also induce angiogenesis by expressing matrix metalloproteinase (MMPs) [27][28][29]. Angiogenesis inhibition therapy has recently become a promising therapeutic strategy for HCC.…”
Section: Tumor-associated Macrophagesmentioning
confidence: 99%
“…VEGF, a potent angiogenic factor, serves a key role in the formation of new blood vessels in CRC (41). VEGF is upregulated in CRC tissues and anti-VEGF therapy has been applied to patients with metastatic CRC (42,43). A previous study demonstrated that CCAT1 downregulation decreased thyroid cancer cell viability, proliferation, migration and invasion, and reduced VEGF expression (44).…”
Section: Discussionmentioning
confidence: 99%